GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » EV-to-FCF

Acerus Pharmaceuticals (TSX:ASP) EV-to-FCF : 0.00 (As of Jun. 16, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Acerus Pharmaceuticals's Enterprise Value is C$0.00 Mil. Acerus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was C$-35.88 Mil. Therefore, Acerus Pharmaceuticals's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Acerus Pharmaceuticals's EV-to-FCF or its related term are showing as below:

TSX:ASP's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.9
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-16), Acerus Pharmaceuticals's stock price is C$0.36. Acerus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was C$-4.169. Therefore, Acerus Pharmaceuticals's PE Ratio for today is At Loss.


Acerus Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Acerus Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals EV-to-FCF Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 479.86 -3.32 -2.56 -1.84 -2.23

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -2.23 -3.45 -2.34 -1.92

Competitive Comparison of Acerus Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's EV-to-FCF falls into.



Acerus Pharmaceuticals EV-to-FCF Calculation

Acerus Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-35.883
=0.00

Acerus Pharmaceuticals's current Enterprise Value is C$0.00 Mil.
Acerus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-35.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acerus Pharmaceuticals  (TSX:ASP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Acerus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.36/-4.169
=At Loss

Acerus Pharmaceuticals's share price for today is C$0.36.
Acerus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.169.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Acerus Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals (TSX:ASP) Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.
Executives
Norma Beauchamp Director
Stephen Robert Gregory Director
Edward Joseph Gudaitis Director, Senior Officer

Acerus Pharmaceuticals (TSX:ASP) Headlines